top of page

CJC-1295 Explained: What the Science Really Says About This Growth Hormone Peptide

1 day ago
5 min read

If you’ve been exploring the world of peptides for recovery, body composition, or anti-aging, you’ve almost certainly run into CJC-1295. It’s one of the most talked-about “growth hormone peptides” out there, promoted for everything from leaner muscle to better sleep to turning back the clock.


But what actually is it, what does the real research show, and what should you genuinely know before considering it? Let’s break it down in detail, honestly, including the parts the marketing tends to skip.


What is CJC-1295?


CJC-1295 is a synthetic (lab-made) analog of a hormone your body already produces called growth hormone-releasing hormone, or GHRH [1][3]. To understand what it does, it helps to understand the chain of command behind your own growth hormone.


Deep in your brain, the hypothalamus releases GHRH, which acts as a signal telling your pituitary gland to release growth hormone (GH) in natural pulses. That growth hormone then travels to the liver and other tissues, prompting the release of insulin-like growth factor 1 (IGF-1), the molecule responsible for many of growth hormone’s downstream effects on muscle, metabolism, and tissue repair [2][3].


CJC-1295 is designed to mimic that very first signal. As a GHRH-receptor agonist, it’s intended to amplify your natural growth hormone pulses rather than replacing growth hormone directly, which is a key distinction from injecting synthetic HGH [2][5].


The DAC vs no-DAC distinction


One thing that confuses a lot of people is that “CJC-1295” actually refers to two related versions [1][2]:


CJC-1295 with DAC (Drug Affinity Complex) is the long-acting version. The DAC technology allows it to bind to albumin in your blood, dramatically extending how long it stays active. This was the genuine scientific innovation behind the compound, giving it a half-life measured in days rather than the minutes of natural GHRH [4][6].


CJC-1295 without DAC (often called Modified GRF 1-29) is the short-acting version, which clears from the body much faster.

This difference matters, because the extended, continuous stimulation from the DAC version behaves quite differently in the body than your natural, pulsing rhythm of growth hormone release.


What the research actually shows


Here’s where we need to be precise, because this is where hype and evidence part ways.


What is well established: CJC-1295 does what it says on the tin in one specific sense. In the key human study, a Phase 1 trial of healthy adults, a single injection produced sustained, dose-dependent increases in growth hormone (raising mean GH levels roughly 2- to 10-fold for six or more days) and in IGF-1 (raising levels about 1.5- to 3-fold for 9 to 11 days) [4]. With repeated dosing, IGF-1 levels stayed above baseline for up to 28 days [4]. So the fundamental claim that CJC-1295 raises growth hormone and IGF-1 is genuinely supported by human data.


What is NOT established: This is the crucial part. Those published human studies measured hormone levels, biomarkers in the blood, not real-world outcomes [2]. In other words, the research confirms CJC-1295 raises GH and IGF-1, but it does not demonstrate that this translates into the benefits people actually want: more muscle, less fat, better recovery, improved skin, or anti-aging effects. Those popular claims are extrapolated from what growth hormone is known to do in general, not proven through outcome trials of CJC-1295 itself [2][6]. No completed trial has ever measured fat loss or muscle gain as an endpoint. The honest summary: it reliably moves the dial on hormone levels, but the leap from “higher IGF-1” to “the body you’re hoping for” remains unproven.


The safety and regulatory picture


This is the section to read slowly, because it’s where the real stakes live.


Short-term tolerability looked reasonable. In the human trials, CJC-1295 was described as relatively well tolerated over the short term, with the most common side effects being injection-site reactions like transient pain, swelling, and redness [1][4]. No serious adverse reactions were reported in those particular studies [4].


But long-term safety data simply doesn’t exist. Short trials in a small number of healthy adults cannot tell us what happens with months or years of use [2][6]. That’s a meaningful gap, not a reassurance.


The IGF-1 and cancer concern. Perhaps the most important theoretical risk: IGF-1 is a growth factor, and elevated IGF-1 has been associated with increased cancer risk in some epidemiological research [7]. Because CJC-1295 is specifically designed to raise IGF-1, there’s a legitimate, biologically plausible concern about it potentially promoting the growth of existing cancers. This is why caution is strongly advised for anyone with a personal history of cancer [7]. Other potential concerns raised in the literature include effects on blood sugar and metabolism [5].


It is not FDA-approved. CJC-1295 is not approved by the FDA for fitness, anti-aging, or wellness use [2][5]. Products sold online exist in an unregulated gray market, where purity, dosing accuracy, and sterility are real question marks. Notably, there is an FDA-approved GHRH analog, sermorelin, that occupies similar territory, which is one reason medical guidance matters when navigating these options [7].


It is banned in sport. CJC-1295 is prohibited by the World Anti-Doping Agency under the growth hormone secretagogue category [5]. For any competitive athlete in a tested sport, using it can mean a ban.


The bottom line


CJC-1295 is a genuinely interesting compound with real science behind one specific claim: it reliably and durably raises growth hormone and IGF-1 levels in humans. That’s not nothing, and it’s more human data than many trendy peptides can claim.


But “raises a hormone level” and “delivers the results you’re picturing” are two very different statements, and the gap between them is filled with unproven assumptions, unknown long-term safety, an unregulated supply chain, and a serious theoretical cancer concern tied to the very mechanism that makes it work. This is not a supplement to experiment with based on a forum post and a vial from an unknown source.


If you’re curious about growth hormone peptides and whether something like CJC-1295, or an FDA-approved alternative, could fit your health goals, the smart move is a real conversation with a knowledgeable medical provider who can review your individual health history, discuss the genuine risks and benefits, run appropriate labs, and ensure anything you consider is sourced and monitored properly.


Want the honest facts about peptides, tailored to you and your goals? Skip the gray-market guesswork. Reach out to our team at Mana Loa Health for a straightforward, no-hype conversation about whether peptide therapy makes sense for you, done safely and with proper medical oversight.


Currently treating patients located in:

Colorado, Florida, Hawaii, and Washington!

Click the link to schedule a consultation today!


-The Mana Loa Health Team


Patient safety is Mana Loa Health's top priority. The information discussed on this blog is not intended to recommend the self management of health problems or wellness. It is not intended to endorse or recommend any particular type of medical treatment or advice. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your healthcare provider. No information contained on this blog should be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider.


References


  1. CJC-1295: FDA Review Presentation on Compounded Peptide (mechanism, forms, Phase 1 safety summary), U.S. FDA, 2024

  2. CJC-1295 Results: What the Research Really Shows (biomarker vs outcome evidence, supervision, regulatory status), 2025

  3. CJC-1295 (overview of GHRH analog mechanism and development), Wikipedia

  4. Teichman SL, et al. Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults (abstract), Journal of Clinical Endocrinology & Metabolism, 2006

  5. CJC-1295: The Modified GHRH for Sustained Growth Hormone Release (not FDA-approved, WADA-banned, metabolic cautions), 2026

  6. CJC-1295: What It Is, Research Evidence, and FDA Status, 2026

  7. CJC-1295: Evidence, Safety, and What the Research Actually Shows (IGF-1/cancer concern, comparison to sermorelin), 2025

 
 
 

Comments


New ManaLoa Logo (1).png

Patients receive 24/7 direct access to their provider through their personalized client portal.

​

https://mana-loa.clientsecure.me

Contact
phone.png

(808) 765-7144

print.png

(808) 865-6979

inbox.png
Hours

Hawaiian Standard Time (HST)

Monday - Saturday : 8am -8pm
​Sunday: 10am-7pm

Virtual Offices
location (1).png
location (1).png

1003 Bishop St Suite #2700

Honolulu, Hawaii 96813

1201 6th Ave W Suite 100 Bradenton, Florida 34205

​​Providing care across Colorado, Hawaii, Florida, and Washington, now open for new patient appointments.

bottom of page